Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Weiss

Showing results (1121-1130 of 1,128) with videos related to

Pageof 113
Sort By:
You have reached the last page of results.This site can display upto 1,128 results.
Arthritis Care & Research|October 22, 2014
Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance projectSarah Ringold, Audrey Hendrickson, Leslie Abramson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 22, 2014
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritisSergio Davì, Francesca Minoia, Angela Pistorio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort StudyDavid A Cabral, Debra L Canter, Eyal Muscal, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of TherapyClaas H Hinze, Dirk Foell, Anne L Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 1, 2018
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive DiseaseDaniel J Lovell, Anne L Johnson, Bin Huang, et al.
Physical Review Letters|September 22, 2023
Tritium Beta Spectrum Measurement and Neutrino Mass Limit from Cyclotron Radiation Emission SpectroscopyA Ashtari Esfahani, S Böser, N Buzinsky, et al.
Vaccine|January 18, 2024
The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022Amy Parker Fiebelkorn, Sara Adelsberg, Rishelle Anthony, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 113

Showing results (1121-1130 of 1,128) with videos related to

Sort By:
Pageof 113
You have reached the last page of results.This site can display upto 1,128 results.
Arthritis Care & Research|October 22, 2014
Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance projectSarah Ringold, Audrey Hendrickson, Leslie Abramson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 22, 2014
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritisSergio Davì, Francesca Minoia, Angela Pistorio, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Comparing Presenting Clinical Features in 48 Children With Microscopic Polyangiitis to 183 Children Who Have Granulomatosis With Polyangiitis (Wegener's): An ARChiVe Cohort StudyDavid A Cabral, Debra L Canter, Eyal Muscal, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 19, 2018
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of TherapyClaas H Hinze, Dirk Foell, Anne L Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 1, 2018
Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive DiseaseDaniel J Lovell, Anne L Johnson, Bin Huang, et al.
Physical Review Letters|September 22, 2023
Tritium Beta Spectrum Measurement and Neutrino Mass Limit from Cyclotron Radiation Emission SpectroscopyA Ashtari Esfahani, S Böser, N Buzinsky, et al.
Vaccine|January 18, 2024
The role of funded partnerships in working towards decreasing COVID-19 vaccination disparities, United States, March 2021-December 2022Amy Parker Fiebelkorn, Sara Adelsberg, Rishelle Anthony, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 17, 2014
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†G von Minckwitz, S Loibl, M Untch, et al.
Pageof 113